Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Onyx's 2012 oncology sales performance.

Onyx Pharmaceuticals, Inc.

Back to the future

Back to the future Increased sales from its two biggest franchises, Enrel and Neulasta, as well as the late 2013 acquisition of Onyx, contributed to its growth.

Pharma's winners and losers in 2013

Pharma's winners and losers in 2013 The acquisition of Onyx towards the end of 2013 also had a minor effect on Amgen's top-line over the latter stages of the year.

Novartis myeloma drug clears phase III trial

Novartis myeloma drug clears phase III trial The market is currently dominated by both Velcade and Celgene's Revlimid (lenalidomide), although other recent entrants - including Onyx' Kyprolis (carfilzomib) and Celgene's pomalidomide - will drive continued growth for the

Nexavar cleared for thyroid cancer by FDA

Nexavar cleared for thyroid cancer by FDA Bayer and Onyx win expansion of oncology drug’s use in US. ... Bayer and Onyx scored a third approval in the US for their oncology drug Nexavar after the Food and Drug Administration (FDA) approved the drug to treat metastatic differentiated thyroid

Pharma deals during August 2013

Pharma deals during August 2013 Timing is of the essence. The Amgen / Onyx saga rumbled on throughout August. ... The final offer represents $125 per share. Perhaps Onyx dallied a little too long.

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs


Add my company
Onyx Health

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...